Introduction
============

Primary systemic therapy (PST) followed by surgery is a standard therapy for advanced breast cancer, including triple-negative breast cancer (TNBC) ([@b1-ol-0-0-9727]--[@b3-ol-0-0-9727]). Since patients with TNBC, which is used as a surrogate term for basal-like breast cancer subtypes, lack expression of estrogen receptor (ER), progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2), no significant advances have yet been made regarding therapies for treating TNBC patients. Therefore, TNBC remains a deadly type of breast cancer, and further study is required to fully understand it. According to previously-reported gene expression analyses, TNBC has a distinct profile with non-TNBC ([@b4-ol-0-0-9727],[@b5-ol-0-0-9727]) and a heterogeneous tumor ([@b6-ol-0-0-9727]). This heterogeneity could be associated with the therapeutic response of PST for TNBC; however, the association between gene expression and PST response is still unknown.

Cell adhesion molecule (CADM) genes encode an immunoglobulin superfamily molecule and protect against malignant conversion and metastasis by maintaining cell-cell adhesion in epithelia ([@b7-ol-0-0-9727],[@b8-ol-0-0-9727]). Expression of CADM1 located on chromosome 11q23.2 was preferentially lost in invasive lesions compared to non-invasive lesions of lung adenocarcinoma ([@b9-ol-0-0-9727]). Several studies have also demonstrated that CADM1 is frequently inactivated in various cancers, including breast cancer ([@b10-ol-0-0-9727]--[@b14-ol-0-0-9727]). By using primary breast cancer specimens and breast cancer cell lines, loss of CADM1 and 4.1B expression has been reported to be associated with the development and progression of breast cancer, especially in invasion and metastasis ([@b15-ol-0-0-9727]). Therefore, *CADM1* works as a tumor suppressor gene in non-small cell lung cancer as well as breast cancer ([@b16-ol-0-0-9727]). *CADM4*, which is located on chromosome 19q13.31, also works as a tumor suppressor gene in renal clear cell carcinoma, colon cancer, and breast cancer ([@b17-ol-0-0-9727]--[@b19-ol-0-0-9727]). We recently demonstrated that CADM1 and CADM4 were less frequently inactivated in TNBC than in non-TNBC ([@b20-ol-0-0-9727]). Our results that the roles of CADM1 and CADM4 in TNBC are different than their in non-TNBC, and those genes may therefore be associated with the therapeutic response to PST for TNBC.

The efficacy of PST for TNBC can be improved by further understanding of the molecular expression levels in individual tumors. Herein, we report the evaluation of CADM1 and CADM4 expression in TNBC patients who had received PST, and try to define a therapeutic response based on CADM1 and CADM4 expression levels.

Materials and methods
=====================

### Patients and tissue samples

Primary invasive breast cancer samples were obtained from patients who had undergone surgical resections with chemotherapy prior to surgery at the Department of Breast Surgery in Fukushima Medical University Hospital, Fukushima, Japan. This cohort consisted of 16 patients who had been enrolled consecutively at the time of surgery between Jan, 2006 and Dec, 2012. All 16 patients had received a core needle biopsy (CNB) at the initial histological diagnosis, after which they received PST; 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) or FEC followed by paclitaxel (PTX) or docetaxel (DTX). The clinical therapeutic response to PST was evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines ([@b21-ol-0-0-9727]), and each case was categorized as complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD). After surgical resection, therapeutic response to PST was evaluated histologically, and the patients were divided into pathological CR (pCR) or non-pCR groups.

Detailed backgrounds of each tissue donor, including age, sex, clinical staging, and hormone status, were collected. Tumor histopathology was classified according to the Union for International Cancer Control (UICC) TNM classification (the 7th classification) ([@b22-ol-0-0-9727]). Written informed consent was obtained from all patients, and the study was approved by the Institutional Review Board of Fukushima Medical University, Japan.

### IHC staining

IHC staining for CADM1 and CADM4 was performed by same method as previously described ([@b20-ol-0-0-9727]). The breast cancer tissue samples were fixed in 10% formalin, embedded in paraffin, cut into 4-µm sections and stained with hematoxylin and eosin (H&E) and other primary antibodies. Rabbit polyclonal antibodies against CADM1 (1:500, C-18, generated by the Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo) and CADM4 (1:500, Bc-2, generated by the Division of Molecular Pathology, Institute of Medical Science, The University of Tokyo, Tokyo, Japan) were used as described previously ([@b17-ol-0-0-9727]). The antibodies used for IHC staining were as follows: Anti-ER (1:500, cat. no. MA5-13191; Dako; Agilent Technologies GmbH, Waldbronn, Germany); and anti-PgR (1:500, cat. no., MA5-12581; Dako; Agilent Technologies GmbH). For HER2 status, the Histofine^®^ Simple Stain HER2 mono assay kit was used (cat. no. 427041; Nichirei Biosciences, Inc., Tokyo, Japan). Analyses of ER, PgR, and HER2 were performed using IHC staining according to the manufacturer\'s protocol. The sections were deparaffinized in xylene, and hydrated using a graded series of ethanol at room temperature. Subsequently, the sections were washed three times in PBS and endogenous peroxidase was blocked with 0.3% in methanol for 30 min at room temperature. Antigens were retrieved by autoclaving the sections on slides in 0.01 M pH 6.0 citrate buffer for 10 min at 121°C. Subsequent to washing in PBS, the sections were incubated in primary antibody overnight at 4°C. A further wash in PBS was followed by treatment with the secondary antibody \[K1491, Dako EnVision kit/horseradish peroxidase (HRP)\] for 30 min at room temperature and diaminobenzidine (K1491, Dako EnVision kit/HRP) was used for staining detection (both from Dako: Agilent Technologies GmbH). Finally, the sections were counterstained with hematoxylin. Expression of these proteins was evaluated using optical microscopy (BX43; Olympus Corporation, Tokyo, Japan) at ×400 magnification.

### Assessment of IHC staining

Stain signals of CADM1 and CADM4 protein levels were detected in the membranes in normal mammary epithelial cells. Cytoplasmic immunoreactivity without membrane staining was defined as aberrant expression. Membranous staining of CADM1 or CADM4 was evaluated by calculating the percentage of cancer cells with membrane expression in the entire area of invasive and non-invasive lesions. The tumors or lesions were then scored as previously described ([@b15-ol-0-0-9727]); those with scores of 1 (11--30% cells with membrane expression), 2 (31--60%) or 3 (61--100%) were defined as positive staining for CADM1 or CADM4 expression, and those with a score of 0 (0--10%) were defined as negative staining. ER, PgR and HER2 expression levels were evaluated semi-quantitatively, with scores representing the ratio of the number of positive staining cells compared with negative cells, as previously described ([@b23-ol-0-0-9727]). Assessment of the staining was performed blindly by two independent investigators, including an experienced pathologist (Dr Akiteru Goto from Akita University, who was the pathologist, and Dr Motonobu Saito from Fukushima Medical University). Any disagreements between the two investigators was resolved by discussion.

### Statistical analysis

Fisher\'s exact test was performed by GraphPad Prism 6 software (GraphPad Software, Inc., La Jolla, CA, USA). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

The clinical characteristics of the 16 TNBC patients are shown in [Table I](#tI-ol-0-0-9727){ref-type="table"}. All patients were female with ages ranging from 33 to 78 years (mean 49.1 years), and had been diagnosed as having invasive ductal carcinoma. The patients included four stage IIA, nine stage IIB, and three stage IIIB patients. The cases received one of the following treatments: PST as FEC only (n=2); FEC followed by PTX (n=7) or FEC followed by DTX (n=7). The clinical tumor responses to PST as evaluated by RECIST were CR (n=4), PR (n=10), SD (n=1), and PD (n=1). The histological diagnoses in the surgical specimens were pCR (n=3) and non-pCR (n=13).

### Associations between CADM1 and CADM4 expression and clinicopathological factors in TNBC

We evaluated CADM1 and CADM4 expression by IHC staining in surgical or CNB specimens from three pCR and 11 non-pCR TNBC patients who received PST ([Table II](#tII-ol-0-0-9727){ref-type="table"}). While surgical specimens are usually used for IHC staining to measure protein expression, the usefulness of IHC staining with CNB specimens at the initial diagnosis is still unknown. Therefore, we firstly compared CADM1 and CADM4 expression between the CNB and surgical specimens. Among the 13 non-pCR cases in our cohort, nine could be used in this comparison, seven of which had an identical staining intensity score for CADM1 and CADM4 between CNB and surgical specimens (non-pCR 3, non-pCR 4, non-pCR 5, non-pCR 6, non-pCR7, non-pCR 12, and non-pCR 13 cases) ([Fig. 1A](#f1-ol-0-0-9727){ref-type="fig"}). Two cases (non-pCR 1 and non-pCR 2 Cases) showed weaker staining intensity in the CNB specimen (score 1) than in the surgical specimen (scores 2 and 3).

Next, we assessed the impact of CADM1 and CADM4 expression on therapeutic responses. Among the 13 non-pCR cases, one exhibited negative CADM1 expression and two showed weak positive CADM1 expression (score 1) in the surgical specimens, while two cases showed weak positive CADM4 expression (score 1) ([Table II](#tII-ol-0-0-9727){ref-type="table"}). Since there were no available resected tumor specimens for IHC staining in three pCR cases, the evaluation of therapeutic responses according to CADM1 and CADM4 expression levels between non-pCR and pCR cases was impossible. Therefore, the CNB specimens were used for this comparison ([Fig. 1B](#f1-ol-0-0-9727){ref-type="fig"}). While all three pCR cases showed strong positive CADM1 expression (score 2 and 3), two cases showed weak positive CADM1 expression (score 1) and 7 cases showed strong CADM1 expression (score 2 and 3) in non-pCR cases (P=1) ([Table III](#tIII-ol-0-0-9727){ref-type="table"}). On the other hand, while one weak positive (score 1) and one strong positive (score 2 and 3) CADM4 expression in pCR cases, two cases showed weak positive CADM1 expression (score 1) and 7 cases showed strong CADM4 expression (score 2 and 3) in non-pCR cases (P=0.49). Although we have expected that loss of or weak positive CADM1 or CADM4 expression may affect therapeutic response, our results lead to no common tendencies.

Discussion
==========

Inactivated expression of CADM1 and CADM4 has been correlated with local invasion, lymph node metastasis, lymphovascular invasion ([@b15-ol-0-0-9727]) and poor prognosis in breast cancer ([@b18-ol-0-0-9727],[@b24-ol-0-0-9727]). Therefore, it is considered that CADM1 and CADM4 suppress tumor development in cases of breast cancer. However, we previously evaluated CADM1 and CADM4 expression in breast cancer and found that those expression levels were less frequently decreased in TNBC cases than in non-TNBC cases ([@b20-ol-0-0-9727]). In the present study, we investigated further into CADM1 and CADM4 expression levels in both CNB and surgical specimens in TNBC patients who received PST. This analysis allowed us to predict therapeutic efficacy using the pair samples of pre- and post-PST. As a result, we revealed that loss or weak positive expression of CADM1 was frequently observed in non-pCR patients. That loss of CADM1 and CADM4 was less associated with tumorigenesis in the TNBC cases than with that in the non-TNBC cases suggests that TNBC is a unique subtype of breast cancer, which requires further examination.

Approximately 80% of TNBC is classified as basal-like breast cancer, which is one of the intrinsic subtypes as categorized by the gene expression profile ([@b4-ol-0-0-9727],[@b5-ol-0-0-9727]). Basal-like breast cancer is different from other intrinsic subtypes, such as luminal A, luminal B, and HER2 overexpressing breast cancer. Therefore, breast cancer should be considered to be a heterogeneous disease, and TNBC should also be considered to be a unique subtype of breast cancer. In addition, TNBC exhibits a high level of genomic instability, resulting in a high level of intratumor heterogeneity ([@b6-ol-0-0-9727]), and is categorized into several distinct subtypes ([@b25-ol-0-0-9727],[@b26-ol-0-0-9727]). Recently, next-generation sequencing (NGS) has progressed significantly and, by using the NGS method, we have revealed gene aberration profiles of breast tumors in adolescent and young adult females ([@b27-ol-0-0-9727]). Noteworthy, the NGS has also revealed intratumor heterogeneity and accelerated the understanding of clonal evolution in cancer ([@b28-ol-0-0-9727],[@b29-ol-0-0-9727]). Phylogenic trees, which were constructed based on clonal (truncal) and subclonal (branched) mutation analyses, uncovered highly important issues regarding malignant tumors. For example, genomic sequencing from different regions of a tumor may sometimes lead to different mutation profiles. When this situation occurs in driver genes, it results in different treatment strategy selection ([@b30-ol-0-0-9727]). Protein expression may also have the same issue, suggesting that it is not possible to analyze data without considering intratumoral heterogeneity. Therefore, we compared CADM1 and CADM4 expression levels between CNB and surgical specimens. Ultrasound-guided CNB was performed to obtain breast cancer tissue samples for pathological diagnosis at the initial diagnosis. After PST, the tumor tissue was resected and compared with a CNB specimen. In our study, both CADM1 and CADM4 expression levels in the CNB specimens were almost consistent with those in the surgical specimens.

The present study has several limitations. First, it is a retrospective study with a small sample size. Second, although we suggest that CADM1 has an anti-PST role in TNBC, no biological functions are proposed. Further large scale and functional studies are required.
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![Representative images of CADM1 and CADM4 immunohistochemical staining of CNB and surgical specimens. (A) A non-pCR case with both positive CADM1 and CADM4 staining in CNB and surgical specimens. (B) A pCR case (pCR 2) with positive CADM1 and positive CADM4 staining in CNB (upper four panels). A pCR case (pCR 3) with positive CADM1 and negative CADM4 staining in CNB (lower four panels). Left low magnification (×100) and right high magnification (×400) panels are shown. A high magnification image (×400) of the region in the black rectangle of the left panel is presented in the right panel. pCR, pathological complete response, CNB; core needle biopsy; CADM, cell adhesion molecule.](ol-17-01-0921-g00){#f1-ol-0-0-9727}

###### 

Clinicophathological characteristics of patients with PST triple negative breast cancer.

  Characteristics                                                        n (%)
  ---------------------------------------------------------------------- ----------
  Age (years)                                                            
    Mean                                                                 49
    Range                                                                33--78
  Sex                                                                    
    Female                                                               16 (100)
  Histological type                                                      
    Invasive carcinoma of no special type                                16 (100)
  TNM stage at initial diagnosis (22)                                    
    I                                                                    0
    IIA                                                                  4 (25)
    IIB                                                                  9 (56)
    IIIA                                                                 0
    IIIB                                                                 3 (19)
  PST regimens                                                           
    FEC                                                                  2 (13)
    FEC+PTX                                                              7 (44)
    FEC+DTX                                                              7 (44)
  Clinical tumor response^[a](#tfn1-ol-0-0-9727){ref-type="table-fn"}^   
    CR                                                                     4 (25)
    PR                                                                   10 (63)
    SD                                                                   1 (6)
    PD                                                                   1 (6)
  PST effect                                                             
    pCR                                                                    3 (19)
    Non-pCR                                                              13 (81)

Clinical therapeutic response to PST was evaluated using the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; PTX, paclitaxel; DTX, docetaxel; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; PST, primary systemic therapy; pCR, pathological complete response.

###### 

Comparison of CADM1 and CADM4 expression at initial diagnosis or surgery in non-pCR and pCR TNBC patients.

  Case         Age (years)   Stage \[initial diagnosis, (22)\]   PST       Specimen   CADM1 score   CADM4 score
  ------------ ------------- ----------------------------------- --------- ---------- ------------- -------------
  Non-pCR 1    45            IIB                                 FEC+DTX   CNB        1             1
                                                                           surgery    2 and 3       2 and 3
  Non-pCR 2    61            IIA                                 FEC+PTX   CNB        1             1
                                                                           surgery    2 and 3       2 and 3
  Non-pCR 3    34            IIA                                 FEC       CNB        2 and 3       2 and 3
                                                                           Surgery    2 and 3       2 and 3
  Non-pCR 4    44            IIB                                 FEC+DTX   CNB        2 and 3       2 and 3
                                                                           Surgery    2 and 3       2 and 3
  Non-pCR 5    46            IIA                                 FEC+DTX   CNB        2 and 3       2 and 3
                                                                           Surgery    2 and 3       2 and 3
  Non-pCR 6    54            IIB                                 FEC+PTX   CNB        2 and 3       2 and 3
                                                                           Surgery    2 and 3       2 and 3
  Non-pCR 7    58            IIB                                 FEC+PTX   CNB        2 and 3       2 and 3
                                                                           Surgery    2 and 3       2 and 3
  Non-pCR 8    44            IIIB                                FEC       CNB        NA            NA
                                                                           Surgery    0             1
  Non-pCR 9    33            IIB                                 FEC+DTX   CNB        NA            NA
                                                                           Surgery    1             2 and 3
  Non-pCR 10   78            IIIB                                FEC+DTX   CNB        NA            NA
                                                                           Surgery    1             2 and 3
  Non-pCR 11   51            IIIB                                FEC+DTX   CNB        NA            NA
                                                                           Surgery    2 and 3       1
  Non-pCR 12   45            IIA                                 FEC+PTX   CNB        2 and 3       2 and 3
                                                                           Surgery    2 and 3       2 and 3
  Non-pCR 13   52            IIB                                 FEC+PTX   CNB        2 and 3       2 and 3
                                                                           Surgery    2 and 3       2 and 3
  pCR 1        40            IIB                                 FEC+PTX   CNB        2 and 3       1
                                                                           Surgery    NA            NA
  pCR 2        50            IIB                                 FEC+PTX   CNB        2 and 3       2 and 3
                                                                           Surgery    NA            NA
  pCR 3        51            IIB                                 FEC+DTX   CNB        2 and 3       0
                                                                           Surgery    NA            NA

FEC, 5-fluorouracil, epirubicin, and cyclophosphamide; PTX, paclitaxel; DTX, docetaxel; CNB, core needle biopsy; NA, not applicable; TNBC, triple negative breast cancer; pCR, pathological complete response.

###### 

Comparison of CADM1 and CADM4 expression at initial diagnosis in non-pCR and pCR TNBC patients.

                  CADM1 score in CNB specimen       CADM4 score in CNB specimen                           
  --------------- ----------------------------- --- ----------------------------- --------------- --- --- ------
  non-pCR (n=9)   2                             7   1.00                          non-pCR (n=9)   2   7   0.49
  pCR (n=3)       0                             3                                 pCR (n=2)       1   1   

TNBC, triple negative breast cancer; pCR, pathological complete response; CNB, core needle biopsy.

Fisher\'s exact test.
